Table 1:
Baseline characteristics and outcomes at database closure or tracing of patients starting antiretroviral therapy in Ancuabe, rural Mozambique.
| All patients (Original outcomes)
n=4492 |
Patients lost to follow-up and
traced (Tracing outcomes) n=752 |
All patients (Corrected
outcomes*)
n=4492 |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Alive | Died | Lost to follow-up | Alive | Died | Not found | Alive | Died | Lost to follow-up | |
| Total | 1631 | 486 | 2375 | 557 | 46 | 149 | 3276 | 761 | 455 |
| Female | 1173 (72%) | 265 (55%) | 1655 (70%) | 406 (73%) | 31 (67%) | 114 (77%) | 2353 (72%) | 443 (58%) | 329 (72%) |
| Male | 458 (28%) | 221 (45%) | 720 (30%) | 151 (27%) | 15 (33%) | 35 (23%) | 923 (28%) | 317 (42%) | 126 (28%) |
| Age [years] | |||||||||
| Median (IQR) | 31 (25 – 40) | 33 (26 – 41) | 30 (24 – 38) | 29 (24 – 38) | 31 (26 – 36) | 30 (24 – 36) | 30 (25 – 39) | 33 (27 – 40) | 31 (24 – 36) |
| WHO clinical stage | |||||||||
| I & II | 1046 (64%) | 129 (27%) | 1383 (58%) | 354 (64%) | 17 (37%) | 90 (60%) | 2024 (62%) | 217 (29%) | 250 (55%) |
| III & IV | 585 (36%) | 357 (73%) | 992 (42%) | 203 (36%) | 29 (63%) | 59 (40%) | 1252 (38%) | 543 (71%) | 205 (45%) |
| Calendar year | |||||||||
| Median (IQR) | 2015 (2013–2016) | 2012 (2010–2013) | 2013 (2011–2015) | 2013 (2012–2014) | 2013 (2011–2013) | 2013 (2012–2014) | 2014 (2012–2015) | 2012 (2010–2014) | 2013 (2012–2014) |
| 2005–2013 | 562 (34%) | 368 (76%) | 1256 (53%) | 324 (58%) | 35 (76%) | 83 (56%) | 1438 (44%) | 554 (73%) | 265 (58%) |
| 2014–2016 | 1069 (66%) | 118 (24%) | 1119 (47%) | 233 (42%) | 11 (24%) | 66 (44%) | 1839 (56%) | 207 (27%) | 190 (42%) |
| CD4 cell count [cells/μL]& | |||||||||
| Median (IQR) | 301 (191 – 434) | 190 (90 – 327) | 296 (170 – 439) | 308 (183 – 447) | 233 (124 – 386) | 288 (160 – 450) | 299 (187 – 438) | 197 (100 – 337) | 307 (200 – 451) |
| Follow-up time [months] | |||||||||
| Total | 51730 | 9301 | 32663 | 14090 | 1367 | 2692 | 93203 | 16956 | 6904 |
| Median (IQR) | 22 (10 – 43) | 10 (3 – 28) | 6 (1 – 19) | 19 (11 – 33) | 23 (14 – 40) | 9 (3 – 26) | 20 (11 – 39) | 15 (5 – 35) | 8 (2 – 23) |
*
after correction using tracing data: Outcomes are revised, and all numbers shown are multiplied by inverse probability weights [ML] and averaged over the 50 imputed datasets. For BMA and RIDGE weights, see supplemental Table S1.
&
after imputation of missing values.